ReviewClinical cardiology2010
Cardio-oncology/onco-cardiology.
Review in Clinical cardiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 83 citations in OpenAlex.
- Targeting NLRP3 inflammasome to mitigate chemotherapy-induced cardiotoxicity: advances in selective inhibitors and natural modulators.Molecular biology reports · 2026Review
- Deciphering the roles of cellular and extracellular non-coding RNAs in chemotherapy-induced cardiotoxicity.Molecular and cellular biochemistry · 2025Review
- Multicohort Epigenome-Wide Association Study of All-Cause Cardiovascular Disease and Cancer Incidence: A Cardio-Oncology Approach.JACC. CardioOncology · 2024Article
- Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system.Cardio-oncology (London, England) · 2023Article
- Precautions When Performing Pericardiocentesis in Patients with Cardiac Tamponade-complicated Malignancy: A Case Report and Review of the Literature.Internal medicine (Tokyo, Japan) · 2023Review
- Regulation of Ion Channel Function in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes by Cancer Cell Secretion Through DNA Methylation.Frontiers in cardiovascular medicine · 2022Article
- Validation of a newly developed questionnaire regarding clinical history in patients with breast and colorectal cancers.ARYA atherosclerosis · 2021Article
- Serum Biomarkers for Chemotherapy Cardiotoxicity Risk Detection of Breast Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology.Oncology reviews · 2021Article
- Cardiovascular Toxicity Induced by Chronic Vincristine Treatment.Frontiers in pharmacology · 2021Article
- Monitoring the heart during cancer therapy.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Differential predictive factors for cardiovascular events in patients with or without cancer history.Medicine · 2019Observational
- Assessment of Cardiotoxicity of Cancer Chemotherapy: The Value of Cardiac MR Imaging.Magnetic resonance imaging clinics of North America · 2019Review
- Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA).Haematologica · 2018Review
- Cardiovascular Risk in Cancer Survivors.Current treatment options in cardiovascular medicine · 2018Review
- Psychological symptoms and subsequent healthy lifestyle after a colorectal cancer diagnosis.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2018Article
- Long-Term and Latent Side Effects of Specific Cancer Types.The Medical clinics of North America · 2017Review
- Assessment of late anthracycline-induced cardiotoxicity byJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Article
- Life-Threatening Hemopericardium Associated with Rivaroxaban.Case reports in cardiology · 2017Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An understanding of onco-cardiology or cardio-oncology is critical for the effective care of cancer patients. Virtually all antineoplastic agents are associated with cardiotoxicity, which can be divided into 5 categories: direct cytotoxic effects of chemotherapy and associated cardiac systolic dysfunction, cardiac ischemia, arrhythmias, pericarditis, and chemotherapy-induced repolarization abnormalities. Radiation therapy can also lead to coronary artery disease and fibrotic changes to the valves, pericardium, and myocardium. All patients being considered for chemotherapy, especially those who have prior cardiac history, should undergo detailed cardiovascular evaluation to optimize the treatment. Serial assessment of left ventricular systolic function and cardiac biomarkers might also be considered in selected patient populations. Cardiotoxic effects of chemotherapy might be decreased by the concurrent use of angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or beta-blockers. Antiplatelet or anticoagulation therapy might be considered in patients with a potential hypercoagulable state associated with chemotherapy or cancer. Open dialogue between both cardiologists and oncologists will be required for optimal patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.